GLP-1 receptor agonists market is projected to grow at a considerable CAGR of around 7% during the forecast period (2020-2026). The increasing advancement in drug development along with the presence of a strong product pipeline is anticipated to drive the growth of the global market. GLP-1 receptor agonists are a category of antidiabetic agents that performs functioning of the glucagon-like peptide. GLP-1 is a natural incretin compound that influences the body functioning once they get released from the gut during digestion. The growing prevalence of obesity and the geriatric population that leads to diabetes are some other factors anticipated to drive the growth of the global market. 

According to the Global Burden of Diseases, obesity is one of the leading factors for premature death and has 4.7 million deaths across the globe in 2017. Around8 % of mortality was attributed to obesity in 2017 across the globe. More than 13% of adults are obese and 39% of adults are overweight across the globe. Increasing the incidence of obesity promotes the chances of developing type2 diabetes which is the most common type of diabetes across the globe. Therefore, the high prevalence of obesity is anticipated to drive the demand for medications that are required in the treatment of type 2 diabetes. However, the failure of medications is anticipated to hinder the growth of the global GLP-1 receptor agonists market. For instance, in July 2017, GlaxoSmithKline Plc had discontinued the manufacturing and distribution of Tanzeum owing to the limited prescription of the drug along with its declining sales. 

 Segmental Outlook  

The GLP-1 receptor agonists market is segmented on the basis of drug type. Based on drug type, the market is segmented into Exenatide (Bydureon, Byetta), LiraglutidE (Victoza), Lixisenatide (Lyxumia), and Dulaglutide (Trulicity). Dulaglutide is anticipated to hold major market share based on drug type during the forecast period. Dulaglutide (Trulicity) is a medication prepared by Eli Lily and Company. It is a prescribed medication for adults with type 2 diabetes to improve blood sugar (glucose). In addition, this medication is used to reduce the risk of major cardiovascular disorders such as heart attack. The increasing number of prescriptions for trulicity owing to its offered benefits is a key factor contributing to the growth of this market segment.

Global GLP-1 Receptor Agonists Market Share by Drug Type, 2019 (%)

Regional Outlook 

The global GLP-1 receptor agonists market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a major market share in the global market during the forecast period. The growing usage of the GLP-1 receptor agonists along with the high R&D expenditure for drug development by the government in the region is the key factor contributing to the high share of the market in the region. In North America, the US is anticipated to hold major market share due to the high prevalence of Type 2 diabetes along with the high per capita healthcare expenditure of the people in the country. According to the American Diabetes Association (ADA), in 2018, 34.2 million Americans, or 10.5% of the population had diabetes in the US. Nearly 32.6 million Americans have type 2 diabetes.

Global GLP-1 receptor agonists Market Growth, by Region 2020-2026

Asia-Pacific will augment with the significant growth rate in the GLP-1 receptor agonists market

Asia-Pacific is anticipated to showcase considerable growth during the forecast period. According to the IDF, in India 77 million people were having diabetes in 2019. The growing pharmaceutical industry along with the growing prevalence of type 2 diabetes in the emerging economies of the Asia-Pacific such as India, South Korea, and China is anticipated to drive the growth of the GLP-1 receptor agonists market in the region. Increasing per capita income and the increased funding for the R&D of the drugs in the untapped economies is anticipated to offer considerable opportunities for the growth of the market in the region.

Market Players Outlook

Bristol Mayer Squibb, Co., Novo Nordisk A/S, Sanofi SA, Eli Lilly & Company, AstraZeneca PLC, and Merck & Co., Inc. are the key players operating in the market. GLP-1 receptor agonists market is still in its nascent stage. Therefore in order to expand the market share the key players of the are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global market.  Furthermore, these players are actively adopting growth strategies such as merger & acquisition, partnership, collaboration, strategic agreement, and new product launches in order to enhance their market share. For instance, in May 2020, Boehringer Ingelheim and Eli Lilly and Company had entered into an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI for the development of treatment of diabetes and cardiovascular diseases. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global GLP-1 receptor agonists market. Based on the availability of data, information related to the products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.